Altimmune Statistics

Total Valuation

Altimmune has a market cap or net worth of $548.42 million. The enterprise value is $252.72 million.

Market Cap	548.42M
Enterprise Value	252.72M

Important Dates

The next estimated earnings date is Tuesday, August 11, 2026, before market open.

Earnings Date	Aug 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Altimmune has 194.47 million shares outstanding. The number of shares has increased by 38.98% in one year.

Current Share Class	194.47M
Shares Outstanding	194.47M
Shares Change (YoY)	+38.98%
Shares Change (QoQ)	+23.70%
Owned by Insiders (%)	0.44%
Owned by Institutions (%)	42.70%
Float	164.20M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	15,233.81
Forward PS	130,575.50
PB Ratio	1.29
P/TBV Ratio	1.93
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	7,020.11
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 29.56, with a Debt / Equity ratio of 0.13.

Current Ratio	29.56
Quick Ratio	29.43
Debt / Equity	0.13
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-35.59

Financial Efficiency

Return on equity (ROE) is -42.75% and return on invested capital (ROIC) is -25.94%.

Return on Equity (ROE)	-42.75%
Return on Assets (ROA)	-24.40%
Return on Invested Capital (ROIC)	-25.94%
Return on Capital Employed (ROCE)	-29.67%
Weighted Average Cost of Capital (WACC)	5.56%
Revenue Per Employee	$632
Profits Per Employee	-$1.60M
Employee Count	57
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -63.42% in the last 52 weeks. The beta is 0.23, so Altimmune's price volatility has been lower than the market average.

Beta (5Y)	0.23
52-Week Price Change	-63.42%
50-Day Moving Average	2.92
200-Day Moving Average	3.87
Relative Strength Index (RSI)	48.96
Average Volume (20 Days)	4,282,872

Short Selling Information

The latest short interest is 39.12 million, so 20.12% of the outstanding shares have been sold short.

Short Interest	39.12M
Short Previous Month	37.64M
Short % of Shares Out	20.12%
Short % of Float	23.83%
Short Ratio (days to cover)	11.79

Income Statement

In the last 12 months, Altimmune had revenue of $36,000 and -$91.08 million in losses. Loss per share was -$0.91.

Revenue	36,000
Gross Profit	-66.05M
Operating Income	-96.21M
Pretax Income	-91.08M
Net Income	-91.08M
EBITDA	-96.10M
EBIT	-96.21M
Loss Per Share	-$0.91

Full Income Statement

Balance Sheet

The company has $331.54 million in cash and $35.85 million in debt, giving a net cash position of $295.69 million or $1.52 per share.

Cash & Cash Equivalents	331.54M
Total Debt	35.85M
Net Cash	295.69M
Net Cash Per Share	$1.52
Equity (Book Value)	283.99M
Book Value Per Share	2.18
Working Capital	323.35M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$71.64 million and capital expenditures -$32,000, giving a free cash flow of -$71.67 million.

Operating Cash Flow	-71.64M
Capital Expenditures	-32,000
Depreciation & Amortization	106,000
Net Borrowing	35.00M
Free Cash Flow	-71.67M
FCF Per Share	-$0.37

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-267,247.22%
Pretax Margin	-253,002.78%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Altimmune does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-38.98%
Shareholder Yield	-38.98%
Earnings Yield	-16.61%
FCF Yield	-13.07%

Analyst Forecast

The average price target for Altimmune is $15.45, which is 447.87% higher than the current price. The consensus rating is "Buy".

Price Target	$15.45
Price Target Difference	447.87%
Analyst Consensus	Buy
Analyst Count	11
Revenue Growth Forecast (3Y)	281.57%
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on September 14, 2018. It was a reverse split with a ratio of 1:30.

Last Split Date	Sep 14, 2018
Split Type	Reverse
Split Ratio	1:30

Scores

Altimmune has an Altman Z-Score of 2.35 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.35
Piotroski F-Score	3